The Future of Vascular Access: Will the Benefits Be Worth the Risk?

1. Raad I. Intravascular-catheter-related infections. Lancet 1998;351:893–7, March 21.

2. Spera G. A healthy future for catheter manufacturers. Medical Device & Diagnostic Industry. 1998;17, November.

3. Collin GR , Ahmadinejad AS , Misse E. Spontaneous migration of subcutaneous central venous catheters. Am Surg 1997;63:322–6.

4. Amow PM , Quimosing EM , Beach M. Consequences of intravascular catheter sepsis. Clin Infect Dis 1993;16:778–4.

5. Banergee SN , Emori TG , Culver DH , et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980–1989. Am J Med 91 1991;(Suppl 3B):86S–9S.

6. Jarvis WJ , Edwards JR , Culver D , et al. Nosocomial infection rates in adult and pediatric intensive care units in the United States. Am J Med 91 1991;(Suppl 3B):185S–91S.

7. Pearson ML , Abrutyne E. Reducing the risk for catheter-related infections: a new strategy. Ann Intern Med 1997;127:304–6.

8. Micrologix Biotech Inc. Micrologix successfully completes phase I clinical trial for the prevention of bloodstream infections. [Online] http://www.mbiotech.com, April 1999:27.

9. Centers for Disease Control, National Nosicomial Infections Surveillance System . National Nosicomial Infections Surveillance (NNIS) Semiannual Report, May 1995. 1995;AJIC 23:377–5.

10. Centers for Disease Control, National Nosicomial Infections Surveillance System . National Nosicomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1998. AJIC 1998;26:522–3.

11. Jarvis WR , Cookson ST , Robles B. Prevention of nosocomial bloodstream infections: a national and international priority. Infect Control Hosp Epidemiol 1996;17:272–5.

12. Linden PK. Clinical implications of nosocomial gram-positive bacteremia and superimposed antimicrobial resistance. Am J Med 1998;104(5A):24S–33S, May 29.

13. Garrett DO , Jochimsen E , Murfitt K , et al. The emergence of decreased susceptibility to vancomycin in staphylococcus epidermidis. Infect Control Hosp Epidemiol 1999;20:167–70.

14. Thylefors JD , Harbarth S , Pittet D. Increasing bacteremia due to coagulase-negative staphylococci: fiction of reality? Infect Control Hosp Epidemiol 1998;19:581–9.

15. Pittet D , Li N , Woolson RF , et al. Microbiological factors influencing the outcome of nosocomial bloodstream infections: a 6-year validated, population-based model. Clin Infect Dis 1997;24:1068–78.

16. Collignon PJ. Intravascular associated sepsis: a common problem. Med J Aust 1994;161:374–8.

17. Conterno LO , Wey SB , Castelo A. Risk factors for mortality in staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 1998;19:32–7.

18. Nucci M , Colombo AL , Silveira F , et al. Risk factors for death in patients with candidemia. Infect Control Hosp Epidemiol 1998;19:846–50.

19. Sotir MJ , Lewis C , Bisher EW , et al. Epidemiology of device-associated infections related to a long-term implantable vascular access device. Infect Control Hosp Epidemiol 1999;20:187–91.

20. O'Grady NP , Barie PS , Bartlett J , et al. Practice parameters for evaluating new fever in critically ill adult patients. Crit Care Med 1998;26:392–408.

21. Craft PS , May J , Dorigo A , et al. Hickman catheters: left-sided insertion, male gender, and obesity are associated with an increased risk of complications. Aust N Z J Med 1996;26:33–9.

22. Ray S , Stacey R , Imrie M , et al. A review of 560 Hickman catheter insertions. Anaesthesia 1996;51:981–5.

23. Nightingale CE , Norman A , Cunningham D , et al. A prospective analysis of 949 long-term central venous access catheters for ambulatory chemotherapy in patients with gastrointestinal malignancy. Eur J Cancer 1997;33:398–403.

24. Goey SH , Verweij J , Bolhuis RLH , et al. Tunnelled central venous catheters yield a low incidence of septicaemia in interleukin-2-treated patients. Cancer Immunol Immunother 1997;44:301–4.

25. Moukarzel AA , Haddad I , Ament ME , et al. 230 patient years of experience with home long-term parenteral nutrition in childhood: natural history and life of central venous catheters. J Ped Surg 1994;29:1323–7.

26. Tolar B , Gould JR. The timing and sequence of multiple device-related complications in patients with long term indwelling Groshong catheters. Cancer 1996;78:1308–13.

27. Timsit JF , Farkas JC , Boyer JM , et al. Central vein catheter-related thrombosis in intensive care patients. Incidence, risk factors, and relationship with catheter-related sepsis. Chest 1998;114:207–13.

28. Raad II , Luna M , Khalil SM. The relationship between the thrombotic and infectious complications of central venous catheters. JAMA 1994;71:1014–16.

29. Didisheim P. Current concepts of thrombosis and infection in artificial organs. ASAIO 1994;40:230–7.

30. Cobos E , Dixon S , Keung YK. Prevention and management of central venous catheter thrombosis. Current Opinion Hematology 1998;5:355–9.

31. Cassidy FP , Jajko AB , Bron KM , et al. Noninfectious complications of long-term venous catheters: Radiologic evaluation and management. AJR 1987;149:671–5.

32. Beck C , Dubois J , Grignon A , et al. Incidence and risk factors of catheter-related deep vein thrombosis in a pediatric intensive care unit: a prospective study. J Pediatrics 1998;133:237–41.

33. Karnik R , Valentin A , Winkler WB. Duplex sonographic detection of internal jugular venous thrombosis after removal of central venous catheters. Clin Cardiol 1993;16:26–9.

34. Chastre J , Cornud F , Bouchama A , et al. Thrombosis as complication of pulmonary artery catheterization via the internal jugular vein: prospective evaluation by phlebography. N Engl J Med 1982;306:278–81.

35. DeCicco M , Matovic M , Balesteri L , et al. Central venous thrombosis: an early and frequent complication in cancer patients bearing long-term silastic catheter: a prospective study. Thrombosis Research 1997;86:101–13.

36. Andrew M , Marzinotto V , Pencharz P , et al. A cross-sectional study of catheter-related thrombosis in children receiving TPN at home. J Pediatrics 1995;126:358–63.

37. Carman TL , Fernandez BB. Issues and controversies in venous thromboembolism. Cleveland Clinic J Med 1999;66:113–23.

38. Prandroni P , Polistena P , Bernardi E , et al. Upper extremity deep vein thrombosis. Risk factors, diagnosis, and complications. Arch Intern Med 1997;157:57–63.

39. Connors AF , Castele RJ , Farhat NZ , et al. Complications of right heart catheterization: a prospective autopsy study. Chest 1985;88:567–72.

40. Hingorani A , Ascher E , Hanson J , et al. Upper extremity versus lower extremity deep vein thrombosis. Am J Surg 1997;174:214–7.

41. Jones RN. Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients. Am J Med 1996;100(Suppl 6A):3S–12S.

42. Strausbaugh LJ. Vancomycin-intermediate Staphylococcus epidermidis: curio or omen? Infect Control Hosp Epidemiol 1999;20:163–5.

43. Raad I , Airahwan A , Rolston K. Staphyloccocus epidermidis: Emerging resistance and need for alternative agents. Clin Infect Dis 1998;26:1182–7.

44. Raad I & the Global Synercid CRGPB Study Group . Dose ranging randomized multicenter open phase I study of quinupristin/dalfopristin versus vancomycin in the treatment of catheter-related gram-positive bacteremia. Final Programme and Book of Abstracts, Twentieth International Congress of Chemotherapy, Sydney, Australia: June 1997 [Abstract 2319].

45. Leclercq R , Courvalin P. Streptogramins. An answer to antibiotic resistance in gram-positive bacteria. The Lancet 1998;352:591–2, August 12.

46. Barriere JC , Bouanchaud DH , Paris JM , et al. Antimicrobial activity against Staphylococcus aureus of semisynthetic injectable streptogramins: RP 59500 and related compounds. J Antimicrob Chemother 1992;30(Suppl A):1–8.

47. Russell AD , Tattawasart U , Maillard JY , et al. Possible link between bacterial resistance and use of antibiotics and biocides. Antimicrob Agents & Chemo 1998;42:2151.

48. Haines KA , Klein DA , McDonnell G , et al. Could antibiotic-resistant pathogens be cross-resistant to hard-surface disinfectants? AJIC 1997;25:439–41.

49. Eng JA , Valena F , Dever LL , et al. Could antibiotic-resistant pathogens be cross-resistant to hard-surface disinfectants? Reply. AJIC 1997;25:441.

50. Eng JA , Shsh L , Valena F , et al. Effectiveness of disinfectants for vancomycin-resistant Enterococcus faecium [Abstract]. AJIC 1996;24:101.

51. US Congress, Office of Technology Assessment : Impacts of antibiotic-resistant bacteria (Doc. No. OTA-H-629). US Government Printing Office, Washington, DC, 1995.

52. Veenstra DL , Saint S , Saha S , et al: Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection. JAMA 1999;281:261–7.

53. Darouiche RO , Raad II , Heard SO , et al. A comparison of two antimicrobial-impregnated central venous catheters. N Engl J Med 1999;340:1–50.

54. Pearson ML. Guideline for the prevention of intravascular-device-related infections. Infect Control Hosp Epidemiol 1996;17:438–72.

55. American Pharmaceutical Association . Managing patients with venous access device-related thrombotic occlusion. IN APhA Guide to Drug Treatment Protocols: A Resource for Creating and Using Disease-Specific Pathways. Author, Washington, DC, 1998, pp 9–20.

56. American Pharmaceutical Association . Managing patients with venous access device-related venous thrombosis. IN APhA Guide to Drug Treatment Protocols: A Resource for Creating and Using Disease-Specific Pathways. Author, Washington, DC, 1998, pp 21–30.

57. American Pharmaceutical Association . Managing infectious complications in patients with venous access devices. IN APhA Guide to Drug Treatment Protocols: A Resource for Creating and Using Disease-Specific Pathways. Author, Washington, DC, 1998, pp 31–9.

58. Ryder M. Peripherally inserted central venous catheters. Nurs Clinics N Am 1993;28:937–72.

59. Ryder M , Scott WL , Helm A. Is downsizing and disbanding specialty care teams a counterproductive strategy for cost reduction in healthcare? Nutrition 1998;14:725–8.

60. Lange BJ , Weiman M , Feuer EJ , et al. Impact of changes in catheter management on infectious complications among children with central venous catheters. Infect Control Hosp Epidemiol 1997;18:326–32.

61. Sherertz R. Look before you leap: discontinuation of an infusion therapy team. Infect Control Hosp Epidemiol 1999;20:99–100.

62. Abi-said D , Raad I , Umphrey J , et al. Infusion therapy team and dressing changes of central venous catheters. Infect Control Hosp Epidemiol 1999;20:101–5.

63. Meier PA , Fredrickson M , Catney M , et al. Impact of a dedicated intravenous therapy team on nosocomial bloodstream infection rates. AJIC 1998;26:388–92.

64. Buggs C , Valadez AM , Lund CA. Evaluating the effectiveness of an intravenous therapy team. Nursing Economics 1993;11: 249–55.

65. Christensen L , Greenough B. Centralized I.V. team provides inpatient and home-care treatment. Nurs Manage 1998;29:69–71.

66. Sherertz RJ , Westbrook DM , Gledhill KS , et al. Description of an infection control course for house officers and medical students. Abstract presented at the eighth annual meeting of the Society for Healthcare Epidemiology of America, Orlando, FL, 1998, April (Abstract 12).

67. Stephenson J. Worry grows as antibiotic-resistant bacteria continue to gain ground. JAMA 1997;278:2049–50.